Cancer Cytogenomics Microarray Consortium Aims to Set Standards for Arrays in Cancer Dx
November 30, 2010
Cancer Cytogenomics Microarray Consortium Aims to Set Standards for Arrays in Cancer Dx
The CCMC will next year carry out a multicenter validation study to demonstrate that the technology is reliable and reproducible enough for clinical use.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Cytogeneticists Say Platform Choice a Question of Personal Preference, Circumstance
August 21, 2012 / BioArray News - Agilent to Debut New CGH and SNP Arrays to Support Cyto, Cancer Research
September 14, 2010 / BioArray News - Consumer Genetics Sales, GWAS, BlueGnome Drive Illumina Q1 Microarray Revenue Growth
April 23, 2013 / BioArray News - In Bid to Court Cancer Cyto Community, OGT Prepares CCMC-Designed Chip for Launch
February 26, 2013 / BioArray News - Affy Files CytoScan with FDA, Plans 'Aggressive' Marketing Campaign to Grow Cyto Business
February 19, 2013 / BioArray News